Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence

BACKGROUND: Osimertinib is an EGFR-TKI that is selective for both EGFR-TKI-sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer (NSCLC). The purpose of this study was conducting a meta-analysis to evaluate the clinical efficacy and safety of osimertinib in the treat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Onco Targets Ther
Egile Nagusiak: Chen, Peng, Chen, Fuchao, Lei, Jiexin, Zhou, Benhong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6296202/
https://ncbi.nlm.nih.gov/pubmed/30588016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182077
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak